TG Therapeutics Provides Regulatory Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
TG Therapeutics (TGTX) PT Lowered to $13 at Goldman Sachs
November 30, 2021 12:55 PM ESTGoldman Sachs analyst Corinne Jenkins lowered the price target on TG Therapeutics (NASDAQ: TGTX) to $13.00 (from $26.00) while maintaining a Sell rating as the ODAC raises new questions on benefit/risk of U2 in CLL.
"Timing of approval decision likely delayed, approvability of U2 in CLL in question," the analyst notes.
... More
